RU2018109979A - Способ получения бензоксазепиновых соединений - Google Patents

Способ получения бензоксазепиновых соединений Download PDF

Info

Publication number
RU2018109979A
RU2018109979A RU2018109979A RU2018109979A RU2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A RU 2018109979 A RU2018109979 A RU 2018109979A
Authority
RU
Russia
Prior art keywords
reacting
reagent
iii
pph
paragraphs
Prior art date
Application number
RU2018109979A
Other languages
English (en)
Russian (ru)
Inventor
Реми АНЖЕЛО
Даниал Р. БОДРИ
Дайан Е. КАРРЕРА
Сушант МАЛХОТРА
Трэвис РЕМАРЧУК
Фредерик СТ-ЖАН
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2018109979A publication Critical patent/RU2018109979A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2018109979A 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений RU2018109979A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015138488A Division RU2649976C2 (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений

Publications (1)

Publication Number Publication Date
RU2018109979A true RU2018109979A (ru) 2019-02-28

Family

ID=50241450

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018109979A RU2018109979A (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений
RU2015138488A RU2649976C2 (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015138488A RU2649976C2 (ru) 2013-03-13 2014-03-12 Способ получения бензоксазепиновых соединений

Country Status (15)

Country Link
US (1) US9303043B2 (https=)
EP (3) EP3845540A1 (https=)
JP (6) JP6363120B2 (https=)
KR (3) KR101871133B1 (https=)
CN (2) CN108929333A (https=)
AR (1) AR095365A1 (https=)
AU (3) AU2014230812B2 (https=)
BR (1) BR112015020716A2 (https=)
CA (6) CA2897618A1 (https=)
IL (1) IL240793A0 (https=)
MX (1) MX2015011438A (https=)
NZ (1) NZ711192A (https=)
RU (2) RU2018109979A (https=)
SG (2) SG10201706760YA (https=)
WO (1) WO2014140073A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180093138A (ko) 2013-12-16 2018-08-20 에프. 호프만-라 로슈 아게 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
AU2016287463B2 (en) 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
KR20190036549A (ko) * 2016-07-29 2019-04-04 니뽄 다바코 산교 가부시키가이샤 피라졸-아미드 화합물의 제조 방법
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018109204A1 (en) 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
WO2000024720A1 (en) * 1998-10-23 2000-05-04 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
KR20040024564A (ko) 2001-07-12 2004-03-20 아베시아 리미티드 마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換5−員窒素含有複素環
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
BRPI0717320A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
KR101083177B1 (ko) * 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
JP2010516680A (ja) * 2007-01-19 2010-05-20 エックスカバリー,インコーポレイテッド キナーゼ阻害薬化合物
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
US8716483B2 (en) * 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
MX2010010659A (es) 2008-03-31 2010-10-26 Genentech Inc Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
MY160064A (en) 2009-09-28 2017-02-15 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
WO2011053688A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
US9090628B2 (en) 2011-03-21 2015-07-28 Genentech, Inc. Benzoxazepin compounds selective for PI3K P110 delta and methods of use
NO3175985T3 (https=) * 2011-07-01 2018-04-28
BR112014028376A2 (pt) 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção

Also Published As

Publication number Publication date
KR101821468B1 (ko) 2018-01-23
EP3404032A2 (en) 2018-11-21
AU2014230812A1 (en) 2015-09-03
EP2970329A1 (en) 2016-01-20
JP2019031493A (ja) 2019-02-28
KR20150119033A (ko) 2015-10-23
JP6442005B2 (ja) 2018-12-19
EP3404032B1 (en) 2025-07-02
HK1215433A1 (zh) 2016-08-26
CA3005103A1 (en) 2014-09-18
JP6663459B2 (ja) 2020-03-11
JP2018008959A (ja) 2018-01-18
SG11201507394RA (en) 2015-10-29
RU2649976C2 (ru) 2018-04-06
EP3404032A3 (en) 2019-03-13
AU2018201393A1 (en) 2018-03-15
IL240793A0 (en) 2015-10-29
CN105377856B (zh) 2018-05-22
KR101871133B1 (ko) 2018-06-25
KR20180070715A (ko) 2018-06-26
AU2014230812B2 (en) 2016-04-07
AU2014230812A8 (en) 2015-09-10
AU2016204432B2 (en) 2017-12-07
CA2897618A1 (en) 2014-09-18
KR20170070270A (ko) 2017-06-21
CN105377856A (zh) 2016-03-02
JP6363120B2 (ja) 2018-07-25
CA3005112A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
EP3404032C0 (en) 2025-07-02
WO2014140073A1 (en) 2014-09-18
JP2020114814A (ja) 2020-07-30
RU2015138488A (ru) 2017-04-20
MX2015011438A (es) 2016-02-03
EP3845540A1 (en) 2021-07-07
AR095365A1 (es) 2015-10-14
CA2948765A1 (en) 2014-09-18
CA3005118A1 (en) 2014-09-18
AU2016204432A1 (en) 2016-07-21
US9303043B2 (en) 2016-04-05
CA2948763A1 (en) 2014-09-18
JP2018150298A (ja) 2018-09-27
US20140275523A1 (en) 2014-09-18
NZ711192A (en) 2019-04-26
BR112015020716A2 (pt) 2017-07-18
JP2016512209A (ja) 2016-04-25
SG10201706760YA (en) 2017-10-30
CN108929333A (zh) 2018-12-04
CA2948763C (en) 2018-04-24

Similar Documents

Publication Publication Date Title
RU2018109979A (ru) Способ получения бензоксазепиновых соединений
JP2018008959A5 (https=)
CY2020006I1 (el) Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk
WO2010125216A3 (es) Preparación de compuestos 5,6-dihidropirido[2,3-d]pirimidin-7(8h)-ona sustituidos
HRP20150571T1 (xx) Supstituirani n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-karboksamidni spojevi kao inhibitori receptora tirozin kinaze tipa iii
CL2007003671A1 (es) Metodo para la preparacion de derivados del acido 2-amino-5-cianobenzoico, utiles como intermediarios para la preparacion de las correspondientes diamidas cianoantranilicas.
BRPI0920001A2 (pt) sistema de produção de água de alta pureza intermitente, sob solicitação
RU2005136234A (ru) Катализатор синтеза этиленоксида
Ito et al. Discovery of spiro [indole-3, 2′-pyrrolidin]-2 (1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP
RU2015113747A (ru) Способ получения соединений тиенопиримидина
CL2008001131A1 (es) Solucion de manoproteinas; proceso para producir dicha solucion de manoproteinas; proceso para estabilizar vino impidiendo o retardando la cristalizacion de sales de acido tartarico.
BRPI0810006A2 (pt) Derivados de purina substituída contendo 2,6-dinitrogênio, a preparação e usos a partir deles
CN106905350B (zh) 一种噻唑并[3,2-α]吡啶衍生物的制备方法及其制备用催化剂
MX373379B (es) Catalizador y proceso para oxicloración de etileno en dicloroetano.
IT1396210B1 (it) Metodo di realizzazione di un dispositivo di rigenerazione di tessuti biologici, particolarmente per la rigenerazione di tessuti appartenenti al sistema nervoso periferico.
EA201291289A1 (ru) Кристаллическое производное тиенопиримидина
CN103613597A (zh) 一种枸橼酸爱地那非的制备工艺
CO6511200A2 (es) Proceso para la preparación de derivados de primidinilacetonitrilo e intermediarios para la sintesis de estos
ES1058046Y (es) Vestidor para bebes con sistema de pesaje
RU2013136948A (ru) Способ получения 5(6)-амино-2-(4-аминофенил)бензимидазола
RU2007105420A (ru) Способ очистки крови от днк-содержащих иммунных комплексов с помощью иммобилизированного гранулированного магнитоуправляемого препарата
Besshejko et al. Numerical model of'Pellet'-target for cyclic accelerators; Chislennaya model''Pellet'-misheni dlya tsiklicheskikh uskoritelej
RU2009137831A (ru) Способ получения катализатора винилацетата
RU2015145487A (ru) Способ получения эрлотиниба
Shelud'ko et al. MORFOLOGIChESKAYa ADAPTATsIYa ORGANOV I TKANEY PRI ZhENSKOM ALKOGOLIZME

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20170313